ADE

ADE
Name	ADE
Field	Immunology, Virology
Related	Antibody, Fc receptor, Neutralizing antibody, Viral pathogenesis

ADE

ADE is a phenomenon in which antibodies enhance the entry or pathogenicity of a pathogen rather than protect the host. It appears in contexts involving antibodies, receptors, and pathogens, and has influenced responses to outbreaks, vaccine design, and therapeutic antibody development. ADE is studied across virology, immunology, and clinical research, with historical and contemporary relevance to diseases, vaccines, and public health policy.

Introduction

Antibody-dependent enhancement has been described in association with outbreaks investigated by teams from Rockefeller Institute for Medical Research, World Health Organization, Centers for Disease Control and Prevention, Institut Pasteur, and university groups at Harvard University, University of Oxford, University of Tokyo, and Karolinska Institutet. Early laboratory reports emerged alongside studies at National Institutes of Health and in field work related to epidemics in Puerto Rico, Thailand, Brazil, India, and Nigeria. The phenomenon has been implicated in case series and trials involving pathogens studied at Walter Reed Army Institute of Research, Pasteur Institute of Dakar, and research programs funded by agencies such as Wellcome Trust, Gates Foundation, and European Commission.

Mechanisms

Mechanistic models invoke interactions among antibodies, antigen, and host receptors characterized in work at Max Planck Institute for Infection Biology, Cold Spring Harbor Laboratory, Scripps Research, and University of California, San Francisco. Studies identify roles for Fc gamma receptors on cells described in histology from Johns Hopkins Hospital and signaling pathways mapped at Massachusetts General Hospital. Complement-mediated pathways were elucidated in experiments at Imperial College London and McGill University. Structural biology contributions from European Molecular Biology Laboratory, Riken, and Stanford University provided cryo-EM and crystallography evidence for antibody–antigen complexes interacting with entry receptors. Cellular tropism shifts described in papers from Yale University, University of Melbourne, McMaster University, and University of São Paulo show how non-neutralizing or subneutralizing antibodies can facilitate uptake via Fc receptors or complement receptors.

Clinical Significance

Clinical correlations come from cohort studies at Mount Sinai Hospital, Royal Brisbane and Women's Hospital, Groote Schuur Hospital, and surveillance networks coordinated by Pan American Health Organization. ADE-like phenomena have influenced severity classifications used by World Health Organization and case definitions applied in trials overseen by Food and Drug Administration and European Medicines Agency. Hospital-based case reports from Universitas Indonesia Hospital, King's College Hospital, and Toronto General Hospital have documented worsened outcomes temporally associated with antibody responses measured in laboratories at Laboratory Corporation of America and academic cores at University of Cape Town. Observational analyses linked to vaccine registries maintained by Public Health England and Japan's National Institute of Infectious Diseases have informed risk–benefit assessments.

Detection and Measurement

Detection methods were standardized in interlaboratory comparisons involving Clinical and Laboratory Standards Institute and assay validation consortia including groups at National Institute for Biological Standards and Control and Paul Ehrlich Institut. In vitro neutralization and enhancement assays developed at Centers for Disease Control and Prevention and Institut Pasteur employ cell lines from repositories such as American Type Culture Collection and readouts validated against standards from National Institute of Standards and Technology. Flow cytometry panels designed at Fred Hutchinson Cancer Research Center and serology platforms at Karolinska Institutet quantify Fc-mediated uptake, while animal challenge studies at Rocky Mountain Laboratories and Pirbright Institute examine pathogenic outcomes. Statistical frameworks from London School of Hygiene & Tropical Medicine and Imperial College London guide interpretation of assay sensitivity, specificity, and predictive value.

Examples in Infectious Diseases

Documented associations involve pathogens investigated by teams at institutions including Oswaldo Cruz Foundation and National University of Singapore. Notable historical and contemporary examples include observations in studies of viruses such as those examined at Centers for Disease Control and Prevention virology units and university labs: flaviviruses studied at Fiocruz, alphaviruses analyzed at Institut Pasteur de la Guyane, and coronaviruses characterized at Wuhan Institute of Virology and University of Hong Kong. Field studies from Ministry of Health, Brazil, Thai Ministry of Public Health, and Philippine Department of Health contributed case data. Animal model evidence came from programs at National Institutes of Health, Institut Pasteur, and Veterinary Research Institute facilities.

Implications for Vaccines and Therapeutics

Vaccine development programs at GlaxoSmithKline, Sanofi, Pfizer, Moderna, and academic vaccine centers such as Oxford Vaccine Group and Walter Reed Army Institute of Research incorporated ADE risk assessments into trial design. Regulatory guidance from Food and Drug Administration, European Medicines Agency, and World Health Organization recommends preclinical and clinical evaluation strategies. Monoclonal antibody development by companies including Regeneron Pharmaceuticals, Gilead Sciences, and research consortia at Broad Institute consider Fc-engineering approaches pioneered at Genentech and Amgen to mitigate enhancement. Public health vaccination campaigns run by Gavi and policy advisories from Centers for Disease Control and Prevention integrate data on enhancement risk when issuing recommendations.

Research and Controversies

Active research communities at Cold Spring Harbor Laboratory, Salk Institute, Institut Pasteur, University of California, Berkeley, and Johns Hopkins Bloomberg School of Public Health debate the prevalence and clinical impact of enhancement phenomena. Controversies have arisen in meta-analyses published by groups at Cochrane Collaboration and in regulatory reviews by European Medicines Agency and Food and Drug Administration concerning interpretation of animal versus human data. Ethical discussions involving institutional review boards at Harvard Medical School, University of Oxford, and Karolinska Institutet address trial risk communication. Ongoing multicenter studies coordinated by World Health Organization and funded by Wellcome Trust and Gates Foundation aim to resolve outstanding questions.

Category:Immunology